title: The prophylactic use of low-dose amphotericin B in bone marrow transplant patients.
abstract: OBJECTIVE
  To evaluate the efficacy of prophylactic low-dose amphotericin B (0.1 mg/kg per day) (LDA) in preventing fungal infections in patients who have had a bone marrow transplant (BMT).
  
  
  METHODS
  Double-blind, randomized, controlled trial in which patients undergoing bone marrow transplantation received intravenous LDA or similar-appearing placebo from the onset of neutropenia until the absolute neutrophil count remained > 0.5 x 10(9)/L, or until high-dose amphotericin B was initiated. Weekly surveillance cultures were obtained from all patients.
  
  
  RESULTS
  Five of 18 patients (28%) randomized to placebo developed documented systemic fungal infections within the first 30 days after transplantation, compared to none of 17 patients who received LDA (P = 0.045). LDA recipients received fewer days of high-dose amphotericin B (P = 0.04) and fewer days of antibiotics (P = 0.008). There were trends towards fewer days of hospitalization (P = 0.14) and improved survival (P = 0.08); these differences were statistically significant among recipients of allogeneic BMT. No adverse effects occurred with LDA therapy.
  
  
  CONCLUSIONS
  LDA appears to be safe and to reduce early systemic fungal infections in BMT recipients. Improved survival was observed among LDA recipients, but this was not directly attributable to the prevention of fungal infection.
authors.affiliation: Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City 84132.
authors.forename: D K
authors.initials: DK
authors.lastname: Riley
authors.forename: A T
authors.initials: AT
authors.lastname: Pavia
authors.forename: P G
authors.initials: PG
authors.lastname: Beatty
authors.forename: F B
authors.initials: FB
authors.lastname: Petersen
authors.forename: J L
authors.initials: JL
authors.lastname: Spruance
authors.forename: R
authors.initials: R
authors.lastname: Stokes
authors.forename: T G
authors.initials: TG
authors.lastname: Evans
mesh_terms: D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D015986:Confounding Factors, Epidemiologic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000666:Amphotericin B